Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model.

Muscle & nerve - 1 Aug 2013

Miciak Jessica J, Warsing Leigh C, Tibbs Maria E, Jasper Jeffrey R, Jampel Sarah B, Malik Fady I, Tankersley Clarke, Wagner Kathryn R

Abstract excerpt

INTRODUCTION: Tirasemtiv is a novel small molecule activator of the fast skeletal muscle troponin complex that produces sensitization of the sarcomere to calcium. Tirasemtiv is currently in Phase II clinical trials for neuromuscular disease. METHODS: We conducted a blinded, randomized, placebo-controlled preclinical study of the effect of tirasemtiv on forearm grip strength, endurance, respiratory physiology, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Creatine Kinase
Share to Laminin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle Fibers, Skeletal

Share to Muscle Strength

Share to Muscular Dystrophies

Share to Physical Endurance

Share to Pyrazines

Share to Troponin

Source

Identifiers

PMID: 23512724
DOI: 10.1002/mus.23848

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model.PMID 23512724Read ↗

Acute and chronic tirasemtiv treatment improves in vivo and in vitro muscle performance in actin-based nemaline myopathy mice.Semantic proximity Read ↗

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions.Semantic proximity Read ↗

P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.Semantic proximity Read ↗

Early mechanical dysfunction of the diaphragm in the muscular dystrophy with myositis (Ttnmdm) model.Semantic proximity Read ↗

Defective excitation-contraction coupling and mitochondrial respiration precede mitochondrial Ca2+ accumulation in spinobulbar muscular atrophy skeletal muscleSemantic proximity Read ↗

Fast Myosin Binding Protein-C is a Vital Regulator in Young and Aged Fast Skeletal Muscle HomeostasisSemantic proximity Read ↗

Novel model of distal myopathy caused by the myosin rod mutation R1500P disrupts acto-myosin bindingSemantic proximity Read ↗

Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscleSemantic proximity Read ↗

Sexually dimorphic skeletal muscle and cardiac dysfunction in a mouse model of limb girdle muscular dystrophy 2i.Semantic proximity Read ↗

Antioxidants Reduce Muscular Dystrophy in the dy<sup>2J</sup>/dy<sup>2J</sup> Mouse Model of Laminin α2 Chain-deficient Muscular DystrophySemantic proximity Read ↗

The adiponectin analogue ALY688-SR attenuates diaphragm fibrosis, atrophy and mitochondrial stress in a mouse model of Duchenne muscular dystrophySemantic proximity Read ↗

A Small-Molecule Approach to Restore a Slow-Oxidative Phenotype and Defective CaMKIIβ Signaling in Limb Girdle Muscular Dystrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.